Orphan Drugs Market

Orphan Drugs Market (Disease Type - Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardiovascular, Metabolic disorders, Endocrinology, and Infectious diseases; Product Type - Biologic and Non-biologic; Distribution Channel - Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and others) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2025

  • Rep Id : TMRGL1254
  • Published On : Sep 2017
  • No. of Pages : 199
  • Category : Pharmaceutical

Section 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights 
 
Section 2 Assumptions and Research Methodology
 
Section 3 Executive Summary
 
Section 4 Market Overview
4.1. Introduction
        4.1.1 Product Type Definition
4.2. Overview
4.3. Market Dynamics 
        4.3.1. Drivers
                         4.3.1.1. Rising prevalence of rare diseases 
                         4.3.1.2. R&D Grants
                         4.3.1.3. Orphan Drugs provide high return on investments
                         4.3.1.4. First-mover advantage
                         4.3.1.5. Focus on awareness programs
                         4.3.1.6. Tax credits and fee waivers
        4.3.2. Restraints
                         4.3.2.1. High cost of treatment
                         4.3.2.2. Dearth of trained medical professionals
                         4.3.2.3. Non-availability of approved drugs worldwide
                         4.3.2.4. Difficulty in recruiting for clinical trials
        4.3.3. Opportunities
                         4.3.3.1. Unmet clinical needs
                         4.3.3.2. Strategic mergers and acquisitions
                         4.3.3.3. Repurposing of drugs
        4.3.4. Trends
4.5. Global Orphan Drugs Market Analysis and Forecasts, 2015–2025  
4.6. Market Outlook
4.7. Porter's Five Forces Analysis
4.8. Orphan Drug Manufacturing Companies – Acquisitions Timeline
4.9. Orphan Drugs Market- SWOT Analysis
4.10. Regulatory Scenario 
4.11. Comparative Analysis of orphan drug policies
4.12. Rare Diseases Prevalence
4.13. Pricing – Orphan Drugs 
4.14. Orphan Drugs – Price Volume Analysis
4.15. Major Conferences
4.16. Major selling Orphan drugs 
4.17. Orphan Drugs – Drug Exclusivity 
4.18. Clinical Trial Analysis
 
Section 5 Global Orphan Drugs Market Analysis and Forecasts, By Disease Type
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast By Disease Type, 2015–2025 
        5.3.1. Oncology        
        5.3.2. Gastrointestinal
        5.3.3. Pulmonary
        5.3.4. Neurology
        5.3.5. Hematology
        5.3.6. Cardiovascular
        5.3.7. Metabolic Disorders
        5.3.8. Endocrinology
        5.3.9. Infectious Diseases
        5.3.10. Others
5.4. Market Attractiveness By Disease Type
 
Section 6 Global Orphan Drugs Market Analysis and Forecasts, By Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product Type, 2015–2025
        6.3.1. Biologic
        6.3.2. Non-biologic
6.4. Market Attractiveness By Product Type
 
Section 7 Global Orphan Drugs Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Distribution Channel, 2015–2025
        7.3.1. Hospital Pharmacies
        7.3.2. Specialty Pharmacies
        7.3.3. Retail Pharmacies
        7.3.4. Others
7.4. Market Attractiveness By Distribution Channel
 
Section 8 Global Orphan Drugs Market Analysis and Forecasts, By Region  
8.1. Key Findings
8.2. Market Value Forecast By Region
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Rest of the World
8.3. Market Attractiveness by Region
 
Section 9 North America Orphan Drugs Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast By Country, 2015-2025
        9.3.1. U.S.
        9.3.2. Canada
9.4. Market Value Forecast By Disease Type, 2015–2025 
        9.4.1. Oncology
        9.4.2. Gastrointestinal
        9.4.3. Pulmonary
        9.4.4. Neurology
        9.4.5. Hematology
        9.4.6. Cardiovascular
        9.4.7. Metabolic Disorders
        9.4.8. Endocrinology
        9.4.9. Infectious Diseases
        9.4.10. Others
9.5. Market Value Forecast By Product Type, 2015–2025
        9.5.1. Biologic
        9.5.2. Non-biologic
9.6. Market Value Forecast By Distribution Channel, 2015–2025
        9.6.1. Hospital Pharmacies
        9.6.2. Specialty Pharmacies
        9.6.3. Retail Pharmacies
        9.6.4. Others
9.7. Market Attractiveness Analysis
        9.7.1. By Country
        9.7.2. By Disease Type
        9.7.3. By Product Type
        9.7.4. By Distribution Channel
 
Section 10 Europe Orphan Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast By Country, 2015-2025
        10.3.1. U.K.
        10.3.2. Germany
        10.3.3. France
        10.3.4. Italy
        10.3.5. Spain 
        10.3.6. Rest of Europe
10.4. Market Value Forecast By Disease Type, 2015–2025 
        10.4.1. Oncology
        10.4.2. Gastrointestinal
        10.4.3. Pulmonary
        10.4.4. Neurology
        10.4.5. Hematology
        10.4.6. Cardiovascular
        10.4.7. Metabolic Disorders
        10.4.8. Endocrinology
        10.4.9. Infectious Diseases
        10.4.10. Others
10.5. Market Value Forecast By Product Type, 2015–2025
        10.5.1. Biologic
        10.5.2. Non-biologic
10.6. Market Value Forecast By Distribution Channel, 2015–2025
        10.6.1. Hospital Pharmacies
        10.6.2. Specialty Pharmacies
        10.6.3. Retail Pharmacies
        10.6.4. Others
10.7. Market Attractiveness Analysis
        10.7.1. By Country
        10.7.2. By Disease Type
        10.7.3. By Product Type
        10.7.4. By Distribution Channel
 
Section 11 Rest of the World Orphan Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast By Country, 2015-2025
        11.3.1. Japan
        11.3.2. Australia
        11.3.3. China
        11.3.4. Brazil
        11.3.5. South Korea 
        11.3.6. Others
11.4. Market Value Forecast By Disease Type, 2015–2025 
        11.4.1. Oncology
        11.4.2. Gastrointestinal
        11.4.3. Pulmonary
        11.4.4. Neurology
        11.4.5. Hematology
        11.4.6. Cardiovascular
        11.4.7. Metabolic Disorders
        11.4.8. Endocrinology
        11.4.9. Infectious Diseases
        11.4.10. Others
11.5. Market Value Forecast By Product Type, 2015–2025
        11.5.1. Biologic
        11.5.2. Non-biologic
11.6. Market Value Forecast By Distribution Channel, 2015–2025
        11.6.1. Hospital Pharmacies
        11.6.2. Specialty Pharmacies
        11.6.3. Retail Pharmacies
        11.6.4. Others
11.7. Market Attractiveness Analysis
        11.7.1. By Country
        11.7.2. By Disease Type
        11.7.3. By Product Type
        11.7.4. By Distribution Channel
 
Section 12 Country Snippets
 
Section 13 Competition Landscape
13.1. Market Player – Competition Matrix (By Tier and Size of companies)
13.2. Market Share Analysis By Company, 2016
13.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)  
        13.3.1. Novartis AG 
                  13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.1.2. Business Overview
                  13.3.1.3. Product Portfolio
                  13.3.1.4. Financial Overview
                  13.3.1.5. SWOT Analysis
                  13.3.1.6. Strategic overview
        13.3.2. Bristol-Myers Squibb Company
                  13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.2.2. Business Overview
                  13.3.2.3. Product Portfolio
                  13.3.2.4. Financial Overview
                  13.3.2.5. SWOT Analysis
                  13.3.2.6. Strategic overview 
        13.3.3. Celgene Corporation
                  13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.3.2. Business Overview
                  13.3.3.3. Product Portfolio
                  13.3.3.4. Financial Overview
                  13.3.3.5. SWOT Analysis
                  13.3.3.6. Strategic overview 
        13.3.4. F. Hoffmann-La Roche Ltd. 
                  13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.4.2. Business Overview
                  13.3.4.3. Product Portfolio
                  13.3.4.4. Financial Overview
                  13.3.4.5. SWOT Analysis
                  13.3.4.6. Strategic overview
        13.3.5. Pfizer, Inc. 
                  13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.5.2. Business Overview
                  13.3.5.3. Product Portfolio
                  13.3.5.4. Financial Overview
                  13.3.5.5. SWOT Analysis
                  13.3.5.6. Strategic overview
        13.3.6. Sanofi S.A. 
                  13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.6.2. Business Overview
                  13.3.6.3. Product Portfolio
                  13.3.6.4. Financial Overview
                  13.3.6.5. SWOT Analysis
                  13.3.6.6. Strategic overview
        13.3.7. Alexion Pharmaceuticals, Inc. 
                  13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.7.2. Business Overview
                  13.3.7.3. Product Portfolio
                  13.3.7.4. Financial Overview
                  13.3.7.5. SWOT Analysis
                  13.3.7.6. Strategic overview
        13.3.8. Eli Lilly and Company
                  13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.8.2. Business Overview
                  13.3.8.3. Product Portfolio
                  13.3.8.4. Financial Overview
                  13.3.8.5. SWOT Analysis
                  13.3.8.6. Strategic overview
        13.3.9. Novo Nordisk A/S 
                  13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.9.2. Business Overview
                  13.3.9.3. Product Portfolio
                  13.3.9.4. Financial Overview
                  13.3.9.5. SWOT Analysis
                  13.3.9.6. Strategic overview
        13.3.10. AstraZeneca plc 
                  13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.10.2. Business Overview
                  13.3.10.3. Product Portfolio
                  13.3.10.4. Financial Overview
                  13.3.10.5. SWOT Analysis
                  13.3.10.6. Strategic overview
        13.3.11. Eisai Co., Ltd.
                  13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.11.2. Business Overview
                  13.3.11.3. Product Portfolio
                  13.3.11.4. Financial Overview
                  13.3.11.5. SWOT Analysis
                  13.3.11.6. Strategic overview
        13.3.12. Daiichi Sankyo Company Limited 
                  13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.12.2. Business Overview
                  13.3.12.3. Product Portfolio
                  13.3.12.4. Financial Overview
                  13.3.12.5. SWOT Analysis
                  13.3.12.6. Strategic overview
        13.3.13. Bayer AG 
                  13.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.13.2. Business Overview
                  13.3.13.3. Product Portfolio
                  13.3.13.4. Financial Overview
                  13.3.13.5. SWOT Analysis
                  13.3.13.6. Strategic overview
        13.3.14. GlaxoSmithKline plc 
                  13.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.14.2. Business Overview
                  13.3.14.3. Product Portfolio
                  13.3.14.4. Financial Overview
                  13.3.14.5. SWOT Analysis
                  13.3.14.6. Strategic overview
        13.3.15. Merck & Co., Inc. 
                  13.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.15.2. Business Overview
                  13.3.15.3. Product Portfolio
                  13.3.15.4. Financial Overview
                  13.3.15.5. SWOT Analysis
                  13.3.15.6. Strategic overview
        13.3.16. Johnson & Johnson 
                  13.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.16.2. Business Overview
                  13.3.16.3. Product Portfolio
                  13.3.16.4. Financial Overview
                  13.3.16.5. SWOT Analysis
                  13.3.16.6. Strategic overview
        13.3.17. Biogen, Inc. 
                  13.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.17.2. Business Overview
                  13.3.17.3. Product Portfolio
                  13.3.17.4. Financial Overview
                  13.3.17.5. SWOT Analysis
                  13.3.17.6. Strategic overview
        13.3.18. Shire plc
                  13.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.18.2. Business Overview
                  13.3.18.3. Product Portfolio
                  13.3.18.4. Financial Overview
                  13.3.18.5. SWOT Analysis
                  13.3.18.6. Strategic overview
        13.3.19. Amgen, Inc.
                  13.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.3.19.2. Business Overview
                  13.3.19.3. Product Portfolio
                  13.3.19.4. Financial Overview
                  13.3.19.5. SWOT Analysis
                  13.3.19.6. Strategic overview

List of Tables

Table 01: Comparative Analysis of orphan drug policies
Table 02: Top selling orphan drugs of 2016
Table 03: Orphan Drugs- Drug Exclusivity Details (of Few Orphan Drugs)
Table 04: Pipeline Analysis
Table 05: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015–2025
Table 06: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
Table 07: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
Table 08: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Region, 2015–2025
Table 09: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Country, 2015–2025
Table 10: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
Table 11: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015–2025
Table 12: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
Table 13: Europe Orphan Drug Market Size (US$ Bn) Forecast, by Country, 2015–2025
Table 14: Europe Orphan Drug Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
Table 15: Europe Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015–2025
Table 16: Europe Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
Table 17: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Country, 2015–2025
Table 18: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
Table 19: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015–2025
Table 20: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025

List of Figures

Figure 01: Global Orphan Drugs Market Size (US$ Mn) and Y-o-Y Growth (%), and Forecast, 2017–2025
Figure 02: Market Value Share By Disease Type (2017)
Figure 03: Market Value Share By Product Type (2017)
Figure 04: Market Value Share By Distribution Channel (2017)
Figure 05: Market Value Share By Region (2017)
Figure 06: Porter’s Five Force Analysis
Figure 07: Orphan Drugs Market- SWOT Analysis
Figure 08: Regulatory Approval Process- The U.S.
Figure 09: Regulatory Approval Process- Europe
Figure 10: Regulatory Approval Process- Japan
Figure 11: Prevalence of Orphan (rare) diseases
Figure 12: Factors contributing to the orphan drugs pricing decision
Figure 13: Pricing of certain orphan drugs (US$ per patient per year)
Figure 14: Factors for high prices of orphan drugs
Figure 15: Orphan Drugs- Price Volume Analysis
Figure 16: Conferences held on Orphan Diseases
Figure 17: Global Orphan Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 18: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Oncology, 2015–2025
Figure 19: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Gastrointestinal, 2015–2025
Figure 20: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Pulmonary, 2015–2025
Figure 21: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Neurology, 2015–2025
Figure 22: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Hematology, 2015–2025
Figure 23: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Cardiovascular,
Figure 24: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Metabolic Disorders, 2015–2025
Figure 25: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Endocrinology,
Figure 26: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Infectious Diseases, 2015–2025
Figure 27: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
Figure 28: Global Orphan Drugs Market Attractiveness, by Disease Type, 2017-2025
Figure 29: Global Orphan Drugs Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 30: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%), by Biologic, 2015–2025
Figure 31: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%), by Non-biologic, 2015–2025
Figure 32: Global Orphan Drugs Market Attractiveness, by Product Type 2017-2025
Figure 33: Global Orphan Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 34: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2015–2025
Figure 35: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Specialty Pharmacies, 2015–2025
Figure 36: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Retail Pharmacies,
Figure 37: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
Figure 38: Global Orphan Drugs Market Attractiveness, by Distribution Channel, 2017-2025
Figure 39: Global Orphan Drugs Market Revenue (US$ Bn) Forecast, 2015–2025
Figure 40: Global Orphan Drugs Market Value Share Analysis, by Region, 2016 and 2025
Figure 41: Global Orphan Drugs Market Attractiveness, by Region, 2017-2025
Figure 42: North America Orphan Drugs Market Size (US$ Bn) and Y-o-Y Growth (%) Forecast, 2015–2025
Figure 43: North America Orphan Drugs Market Attractiveness Analysis, by Country, 2017–2025
Figure 44: North America Orphan Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 45: North America Orphan Drugs Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 46: North America Orphan Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 47: North America Orphan Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 48: North America Orphan Drugs Market Attractiveness Analysis, by Product Type, 2017–2025
Figure 49: North America Orphan Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 50: North America Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2017–2025
Figure 51: Europe Orphan Drug Market Size (US$ Bn) Forecast, 2015–2025
Figure 52: Europe Market Attractiveness Analysis, by Country, 2017–2025
Figure 53: Europe Orphan Drug Market Value Share Analysis, by Country, 2016 and 2025
Figure 54: Europe Orphan Drug Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 55: Europe Orphan Drug Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 56: Europe Orphan Drug Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 57: Europe Orphan Drug Market Attractiveness Analysis, by Product type, 2017–2025
Figure 58: Europe Orphan Drug Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 59: Europe Orphan Drug Market Attractiveness Analysis, by Disease Type, 2017–2025
Figure 60: Rest of the World Orphan Drugs Market Size (US$ Bn)  and Y-o-Y Growth (%) Forecast, 2015–2025
Figure 61: Rest of the World Market Attractiveness Analysis, by Country, 2017–2025
Figure 62: Rest of the World Orphan Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 63: Rest of the World Orphan Drugs Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 64: Rest of the World Orphan Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 65: Rest of the World Orphan Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 66: Rest of the World Orphan Drugs Market Attractiveness Analysis, by Product Type, 2017–2025
Figure 67: Rest of the World Orphan Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 68: Rest of the World Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2017–2025
Figure 69: Global Orphan Drugs Market Share Analysis, by Company (2016)
Figure 70: Novartis AG, Breakdown of Net Sales, by Region, 2016
Figure 71: Novartis AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 72: Bristol-Myers Squibb Company, Breakdown of Net Sales, by Region, 2016
Figure 73: Bristol-Myers Squibb Company, Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 74: Celgene Corporation, Breakdown of Net Sales, by Region, 2016
Figure 75: Celgene Corporation, Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 76: F. Hoffmann-La Roche Ltd., Breakdown of Net Sales (Pharmaceutical Division), by Region, 2016
Figure 77: F. Hoffmann-La Roche Ltd., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 78: Pfizer, Inc., Breakdown of Net Sales, by Region, 2016
Figure 79: Pfizer, Inc., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 80: Sanofi S.A., Breakdown of Net Sales, by Region, 2016
Figure 81: Sanofi S.A., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 82: Alexion pharmaceuticals, Inc., Breakdown of Net Sales, by Region, 2016
Figure 83: Alexion pharmaceuticals, Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 84: Eli Lilly and Company, Breakdown of Net Sales, by Region, 2016
Figure 85: Eli Lilly and Company, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 86: Novo Nordisk A/S, Breakdown of Net Sales, by Region, 2016
Figure 87: Novo Nordisk A/S, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 88: AstraZeneca plc, Breakdown of Net Sales, by Region, 2016
Figure 89: AstraZeneca plc, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 90: Eisai Co., Ltd., Breakdown of Net Sales, by Region, 2016
Figure 91: Eisai Co., Ltd., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 92: Daiichi Sankyo Company Limited, Breakdown of Net Sales, by Region, 2016
Figure 93: Daiichi Sankyo Company Limited, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 94: Bayer AG, Breakdown of Net Sales, by Region
Figure 95: Bayer AG, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 96: GlaxoSmithKline plc, Breakdown of Net Sales, by Region, 2016
Figure 97: GlaxoSmithKline plc, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 98: Merck & Co., Inc., Breakdown of Net Sales, by Region, 2016
Figure 99: Merck & Co., Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 100: Johnson & Johnson, Breakdown of Net Sales, by Region, 2016
Figure 101: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 102: Biogen, Inc., Breakdown of Net Sales, by Region, 2016
Figure 103: Biogen, Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 104: Shire plc, Breakdown of Net Sales, by Region, 2016
Figure 105: Shire plc, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 106: Amgen, Inc., Breakdown of Net Sales, by Region, 2016
Figure 107: Amgen, Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016